Nixoa will attend the 36th Annual Piper Sandler Healthcare Conference

Niksoa will take part in the film “Piper Sandler 36”^th Annual Healthcare Conference

Mont Saint-Guibert, Belgium – November 20, 2024 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops revolutionary treatment alternatives for obstructive sleep apnea (OSA) through neuromodulation, today announced that the Company will participate in the Piper Sandler 36 program.^th The Annual Healthcare Conference will take place on Wednesday, December 4, 2024. The Company plans to present at 2:00 pm ET on the same day via webcast.

A live audio webcast of the presentation will be available online on the Investor Relations page of the Company’s website at: investors.nyxoah.com.

About Niksoa
Nyxoah is reinventing sleep for the billions of people living with obstructive sleep apnea (OSA). We are a medical technology company developing revolutionary treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free sublingual neuromodulation device that is inserted through a single incision under the chin and controlled via a wearable device. Through our commitment to innovation and clinical evidence, we have demonstrated best-in-class results in reducing the burden of OSA.

Following the successful completion of the BLAST OSA study, the Genio® system received the European CE mark in 2019. Nyxoah has had two successful IPOs: on Euronext Brussels in September 2020 and Nasdaq in July 2021. Following positive results from the BETTER SLEEP trial, Nyxoah received CE approval to expand its therapeutic indication to patients with complete concentric collapse (CCC), currently contraindicated in competitive therapy. Additionally, the company announced positive results from the pivotal DREAM IDE study to seek FDA approval and commercialization in the United States.

Caution – CE marking since 2019. Device for research in the USA. Restricted by US federal law to research use in the United States.

FORWARD-LOOKING STATEMENTS

Certain statements, beliefs and opinions in this press release are forward-looking and reflect Nyxoah’s current expectations and beliefs regarding the Genio® System; planned and ongoing clinical studies of the Genio® system; potential benefits of the Genio® system; Nyxoah’s objectives regarding the development, regulation and potential use of the Genio® System; the utility of clinical data for potential FDA approval of the Genio® system; and potential FDA approval and entry into the U.S. market. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that may cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the results and financial consequences of the plans and activities described herein. In addition, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of Nyxoah’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities Division and the Exchange Commission ( “SEC”) dated March 20, 2024, as well as subsequent reports that Nixoa files with the SEC. A variety of factors, including, but not limited to, changes in demand, competition and technology, could cause actual events, performance or results to differ materially from any anticipated development. The forward-looking statements contained in this press release regarding past trends or performance are not guarantees of future results and should not be taken as a representation that such trends or performance will continue in the future. In addition, even if actual results or events are consistent with the forward-looking statements contained in this press release, those results or events may not be indicative of results or events in future periods. No representations or warranties are made regarding the accuracy or fairness of such forward-looking statements. As a result, Nyxoah expressly disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which they are based. Claims regarding appearance are reasonable unless specifically required by law or regulation. Neither Nyxoah, nor its advisors or representatives, nor any of its subsidiaries, nor the officers or employees of such entities, warrants that the assumptions underlying such forward-looking statements are free from errors or accepts any responsibility for the future accuracy of forward-looking statements. contained in this press release, or the actual occurrence of forward-looking events. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Niksoa
John Landry, Chief Financial Officer
[email protected]

For the media
In the USA
FINN Partners – Glenn Silver
[email protected]

In Belgium/France
Behind the Scenes – Gunther De Backer
[email protected]

International/Germany
MC Services – Anne Henneke
[email protected]

ENGLISH_NYXH Public Relations Consulting Piper Conf